Vir Biotechnology

vir.bio

Vir Biotechnology is a commercial-stage immunology company focused on developing antibody-based medicines to address critical health challenges, including COVID-19 and Ebola. The company leverages its next-generation antibody platform and PRO-XTEN™ masking technology to rapidly advance therapeutic candidates from concept to clinic. With a strong emphasis on infectious diseases, particularly hepatitis delta and hepatitis B, Vir is also exploring strategic programs in oncology. Their experienced leadership team is dedicated to delivering transformative options for patients, positioning Vir as a key player in the immunology space.